Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
← catalyst calendarSponsored by Kymera Therapeutics, Inc. (industry) · KYMR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
22actual
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-17 | actual | When the study began enrolling |
| Primary completion | 2025-11-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-10 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Intervention
- Drug: KT-621
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs)
measured From enrollment through the safety follow-up visit on Day 43
Incidence of treatment-emergent potentially clinically-significant abnormalities in electrocardiogram (ECG) results, vital signs, or laboratory test results from the serum chemistry, hematology (with differential), chemistry, or coagulation panels.
measured From enrollment through the safety follow-up visit on Day 43
Permalink · KYMR's whole pipeline · Catalyst calendar · Every registered study · What changed